Lee Chan Henry 4

What Happened

• Lee Chan Henry, Senior Vice President and General Counsel of BeOne Medicines (ONC), executed several option/derivative transactions and sold shares on July 8, 2026. He exercised three derivative instruments to acquire a total of 664 shares at exercise prices of $194.47, $213.32 and $159.03 (total cash paid = $127,196). The same day he sold 664 shares in an open-market transaction at $302.46 each for proceeds of $200,833 (sale effected under a Rule 10b5-1 trading plan). The filing also reports conversion/settlement of additional derivative instruments (2,626; 3,458; and 2,548 units) shown as dispositions at $0.00, reflecting conversion/settlement rather than cash sales.

Key Details

• Transaction date: July 8, 2026.
• Exercised/acquired: 202 shares @ $194.47 ($39,283); 266 shares @ $213.32 ($56,743); 196 shares @ $159.03 ($31,170). Total paid = $127,196.
• Sold: 664 shares @ $302.46, proceeds = $200,833. Sale under a Rule 10b5-1 plan adopted May 29, 2026 (Footnote F2).
• Other derivative dispositions: 2,626; 3,458; 2,548 reported as disposed at $0.00 (these are conversions/settlements of derivative securities).
• Footnote: Each American Depositary Share (ADS) represents 13 ordinary shares (F1). Vesting schedules for reported derivative awards are noted in F4–F6.
• Shares owned after the transactions: not specified in the provided filing summary.
• Filing timeliness: Report covers 07/08/2026 and was filed 07/10/2026 (timely Form 4 filing).

Context

• Exercise vs sale: The filing shows option/derivative exercises (cash paid for exercise) and an immediate open-market sale of the same number of shares the same day. That pattern results in net proceeds (sale proceeds minus exercise cost) but is not by itself a statement of future sentiment. The sale was executed under a pre-established 10b5-1 plan (F2), which schedules trades in advance.
• Zero-dollar "disposed" entries refer to conversion/settlement of derivative securities into underlying shares (not cash sales).
• Be factual: these are company-reported transactions; motives are not disclosed.